Technical Analysis for CLSN - Celsion Corporation

Grade Last Price % Change Price Change
grade D 2.17 2.36% 0.05
CLSN closed up 2.36 percent on Wednesday, March 20, 2019, on 79 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Flat Down
See historical CLSN trend table...

Date Alert Name Type % Chg
Mar 20 Crossed Above 50 DMA Bullish 0.00%
Mar 20 Stochastic Reached Oversold Weakness 0.00%
Mar 20 Oversold Stochastic Weakness 0.00%
Mar 19 50 DMA Resistance Bearish 2.36%
Mar 19 Spinning Top Other 2.36%
Mar 19 Calm After Storm Range Contraction 2.36%
Mar 19 NR7 Range Contraction 2.36%
Mar 19 NR7-2 Range Contraction 2.36%
Mar 19 Down 3 Days in a Row Weakness 2.36%
Mar 18 Fell Below 20 DMA Bearish 1.88%

Older signals for CLSN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company develops ThermoDox, a liposomal encapsulation of doxorubicin, which is under Phase III clinical trial for primary liver cancer; under phase II clinical trial for colorectal liver metastasis; and under phase II clinical trial for treatment of recurrent chest wall breast cancer. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. for ThermoDox; and a joint research agreement with Royal Philips Electronics to evaluate the combination of Philips' high intensity focused ultrasound with its ThermoDox to determine the potential of this combination to treat various cancers. The company was founded in 1982 and is based in Lawrenceville, New Jersey.
Medicine Cancer Clinical Medicine Chemotherapy Cancers Ultrasound Antineoplastic Drugs Drug Development Hepatocellular Carcinoma Hepatology Anthracyclines Doxorubicin High Intensity Focused Ultrasound
Is CLSN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.48
52 Week Low 1.35
Average Volume 134,148
200-Day Moving Average 2.4152
50-Day Moving Average 2.1608
20-Day Moving Average 2.2333
10-Day Moving Average 2.277
Average True Range 0.1535
ADX 22.27
+DI 21.5007
-DI 16.7342
Chandelier Exit (Long, 3 ATRs ) 2.1695
Chandelier Exit (Short, 3 ATRs ) 2.4915
Upper Bollinger Band 2.4294
Lower Bollinger Band 2.0372
Percent B (%b) 0.34
BandWidth 17.561456
MACD Line 0.021
MACD Signal Line 0.0416
MACD Histogram -0.0205
Fundamentals Value
Market Cap 18.12 Million
Num Shares 8.35 Million
EPS -5.58
Price-to-Earnings (P/E) Ratio -0.39
Price-to-Sales 47.77
Price-to-Book 2.54
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.34
Resistance 3 (R3) 2.33 2.27 2.31
Resistance 2 (R2) 2.27 2.23 2.27 2.30
Resistance 1 (R1) 2.22 2.20 2.25 2.23 2.29
Pivot Point 2.16 2.16 2.17 2.16 2.16
Support 1 (S1) 2.11 2.12 2.14 2.12 2.05
Support 2 (S2) 2.05 2.09 2.05 2.04
Support 3 (S3) 2.00 2.05 2.03
Support 4 (S4) 2.01